PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17481552-8	2007	Salicylate inhibits COX-2 transcriptional activation in quiescent cells but not in serum-driven proliferating cells by blocking C/EBPbeta DNA binding.	Salicylates	0-10	CCAAT enhancer binding protein beta	Homo sapiens	128-137	
15738002-0	2005	Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate.	Salicylates	129-139	CCAAT enhancer binding protein beta	Homo sapiens	47-82	
16963620-6	2006	We propose that salicylate inhibits C/EBPbeta binding at 4 h and C-Rel binding at 8 and 24 h by targeting related kinases.	Salicylates	16-26	CCAAT enhancer binding protein beta	Homo sapiens	36-45	
15738002-1	2005	We have previously shown that salicylate at a pharmacological concentration suppresses CCAAT/enhancer-binding protein beta (C/EBPbeta) binding, thereby reducing cyclooxygenase-2 (COX-2) and inducible nitric-oxide synthase expression (Saunders, M. A., Sansores-Garcia, L., Gilroy, D. W., and Wu, K. K. (2001) J. Biol.	Salicylates	30-40	CCAAT enhancer binding protein beta	Homo sapiens	87-122	
15738002-1	2005	We have previously shown that salicylate at a pharmacological concentration suppresses CCAAT/enhancer-binding protein beta (C/EBPbeta) binding, thereby reducing cyclooxygenase-2 (COX-2) and inducible nitric-oxide synthase expression (Saunders, M. A., Sansores-Garcia, L., Gilroy, D. W., and Wu, K. K. (2001) J. Biol.	Salicylates	30-40	CCAAT enhancer binding protein beta	Homo sapiens	124-133	
15738002-12	2005	We conclude that salicylate inhibits C/EBPbeta-mediated COX-2 transcriptional activation by blocking RSK activity and Ras signaling pathway.	Salicylates	17-27	CCAAT enhancer binding protein beta	Homo sapiens	37-46	
15626591-5	2005	This review highlights the importance of C/EBP beta and NF-kappa B in COX-2 transcriptional activation by proinflammatory mediators and as targets of inhibition by endogenous molecules such as melatonin and natural products including salicylate and polyphenols.	Salicylates	234-244	CCAAT enhancer binding protein beta	Homo sapiens	41-51	
12379662-0	2002	Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway.	Salicylates	0-10	CCAAT enhancer binding protein beta	Homo sapiens	104-139	
12379662-5	2002	Salicylate at pharmacological concentrations is capable of suppressing the early phase of NOS-2 and COX-2 expression by blocking C/EBPbeta binding.	Salicylates	0-10	CCAAT enhancer binding protein beta	Homo sapiens	129-138	
15199473-4	2003	Aspirin and salicylate at therapeutic concentrations inhibit COX-2 protein expression through interference with binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its cognate site on COX-2 promoter/enhancer.	Salicylates	12-22	CCAAT enhancer binding protein beta	Homo sapiens	123-158	
15199473-4	2003	Aspirin and salicylate at therapeutic concentrations inhibit COX-2 protein expression through interference with binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its cognate site on COX-2 promoter/enhancer.	Salicylates	12-22	CCAAT enhancer binding protein beta	Homo sapiens	160-169	
11278846-5	2001	These findings indicate that contrary to the current view that salicylate acts via inhibition of nuclear factor kappaB the pharmacological actions of aspirin and salicylates are mediated by inhibiting CCAAT/enhancer-binding protein beta binding and transactivation.	Salicylates	162-173	CCAAT enhancer binding protein beta	Homo sapiens	201-236